Biohaven names new discovery head as CSO shifts to part-time role Jul 9, 2026 05:01PM
Biohaven completes enrollment in focal epilepsy drug trial Jun 30, 2026 07:31AM
Biohaven Pharma (BHVN) call put ratio 7.5 calls to 1 put as share price down 4.7% Jun 29, 2026 03:27PM
BofA Securities Downgrades Biohaven Pharma (BHVN) to Underperform Jun 29, 2026 06:13AM
Increasing unusual option volume: BHVN DOMO CLPT OIH CVLT PEGA OTLK VT Jun 17, 2026 10:15AM
View Older Stories

Jun 1, 2026 07:31AM Biohaven begins first human trial of brain-penetrant drug BHV-8100
May 27, 2026 10:16AM Raymond James on Biohaven Pharma (BHVN) with shares up 7%: 'Promising Degrader Data Sets Ahead of R&D Day'
May 27, 2026 07:31AM Biohaven reports positive patient data for autoimmune disease drugs
May 26, 2026 07:31AM Biohaven shares clinical data on epilepsy drug opakalim
May 12, 2026 06:52AM H.C. Wainwright Reiterates Neutral Rating on Biohaven Pharma (BHVN)
May 4, 2026 05:11PM Biohaven Pharma (BHVN) Misses Q1 EPS by 4c
May 4, 2026 04:26PM Biohaven Pharma (BHVN) files mixed shelf
Apr 13, 2026 05:18AM Canaccord Starts Biohaven Pharma (BHVN) at Buy
Apr 2, 2026 05:09AM Biohaven Pharma (BHVN) PT Raised to $17 at Citi
Mar 16, 2026 05:28PM Biohaven Pharma (BHVN) PT Raised to $28 at Jefferies
Mar 9, 2026 01:55PM Raymond James on Biohaven Pharma (BHVN): 'results continue to highlight an opportunity for opakalim'
Mar 4, 2026 06:45AM Biohaven Pharma (BHVN) PT Lowered to $10 at H.C. Wainwright
Mar 3, 2026 02:43PM Leerink Partners Reiterates Outperform Rating on Biohaven Pharma (BHVN), lowers EPS estimates
Mar 3, 2026 09:01AM Biohaven Pharma (BHVN) PT Raised to $23 at RBC Capital
Mar 3, 2026 08:43AM Piper Sandler: 'Biohaven Pharma (BHVN) Gearing Up for a Catalyst-Rich 2026'
Mar 2, 2026 08:18PM Biohaven Pharma (BHVN) Tops Q4 EPS by 28c
Feb 23, 2026 08:43AM Piper Sandler on Biohaven Pharma (BHVN): 'We like the risk/reward at current levels'
Feb 5, 2026 04:21PM Goldman Sachs Starts Biohaven Pharma (BHVN) at Buy
Jan 21, 2026 05:04AM RBC Capital Upgrades Biohaven Pharma (BHVN) to Outperform
Jan 12, 2026 01:44PM Bairdon Biohaven (BHVN): 'e think case studies from today's presentation answers the major question lingering for BHV-1400'
Jan 12, 2026 11:20AM Biohaven reports early patient data from protein degrader programs
Dec 26, 2025 08:18AM Stifel Reiterates Xenon Pharmaceuticals (XENE) at Buy following Biohaven's failure
Dec 26, 2025 06:40AM H.C. Wainwright Reiterates Neutral Rating on Biohaven Pharmaceutical Holding (BHVN)
Dec 26, 2025 06:08AM Biohaven Pharma (BHVN) call put ratio 1 call to 1 put as share price lower before the bell
Dec 11, 2025 07:02AM Biohaven shares cancer drug trial results at European oncology meeting
Dec 3, 2025 06:07AM H.C. Wainwright Downgrades Biohaven Pharmaceutical Holding (BHVN) to Neutral
Nov 26, 2025 04:18AM UBS Downgrades Biohaven Pharmaceutical Holding (BHVN) to Neutral
Nov 17, 2025 07:38AM Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $26 at Morgan Stanley
Nov 12, 2025 08:35AM Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $14 at Citi
Nov 11, 2025 04:29AM William Blair Reiterates Market Perform Rating on Biohaven Pharmaceutical Holding (BHVN)
Nov 10, 2025 07:40AM Biohaven Pharma (BHVN) Tops Q3 EPS by 24c
Nov 6, 2025 08:37AM Piper Sandler Slashes Biohaven Pharmaceutical (BHVN) Stock PT as 'FDA Says No to Troriluzole'
Nov 6, 2025 02:23AM Bernstein SocGen Group Downgrades Biohaven Pharmaceutical Holding (BHVN) to Market Perform
Nov 5, 2025 04:09PM Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $15 at Leerink Partners
Nov 5, 2025 03:33PM BofA Securities Downgrades Biohaven Pharmaceutical Holding (BHVN) to Neutral
Nov 5, 2025 10:51AM Raymond James Comments on Biohaven (BHVN) Post Management Call
Nov 5, 2025 10:00AM William Blair Downgrades Biohaven Pharmaceutical Holding (BHVN) to Market Perform
Nov 5, 2025 08:20AM JPMorgan on Biohaven Pharmaceutical (BHVN): 'expect the stock to be under some pressure'
Nov 5, 2025 08:19AM William Blair on Biohaven (BHVN): 'Expect Weakness'
Nov 5, 2025 08:17AM Morgan Stanley on Biohaven (BHVN): 'The next catalyst for the stock is Opakalim (BHV-7000; Kv7 activator) Ph2/3 data in major depressive disorder (MDD)'
Nov 5, 2025 08:16AM Raymond James on Biohaven Pharmaceutical Holding (BHVN): 'Meaningful Value Remains', 'Sticking with it'
Nov 5, 2025 06:10AM Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $42 at Baird
Nov 5, 2025 01:56AM FDA rejects Biohaven drug application for rare brain disorder
Nov 3, 2025 10:00AM Truist: 'QURE Update Minimal Read-Through To PTCT & WVE, In Our View'
Nov 3, 2025 09:24AM Raymond James on Biohaven (BHVN) Amid News Shock: 'QURE Sympathy Move Seems Misplaced'
Nov 3, 2025 07:38AM Biohaven Pharma (BHVN) Weakness May Be Tied to uniQure (QURE) Setback in Huntington's Disease
Sep 17, 2025 05:55AM Citi Starts Biohaven Pharmaceutical Holding (BHVN) at Buy
Sep 16, 2025 09:32AM Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $26 at UBS
Sep 10, 2025 09:16AM RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
Aug 30, 2025 04:00PM Why public perception matters so much for biotech valuations
View Older Stories